Michael Farwell

faculty photo
Assistant Professor of Radiology at the Hospital of the University of Pennsylvania
Active Radiologist, Pennsylvania Hospital
Active Radiologist, Penn Presbyterian Medical Center
Attending, Hospital of the University of Pennsylvania
Radiologist, Phoenixville Hospital
Radiologist, Chester County Hospital
Department: Radiology

Contact information
Hospital of the University of Pennsylvania
Department of Radiology
Division of Nuclear Medicine and Clinical Molecular Imaging
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-662-7750
Fax: 215-349-5843
B.S. (Chemistry)
Union College, 1997.
M.A. (Chemistry)
Harvard University, 2002.
M.D. (Medicine)
Columbia University College of Physicians and Surgeons, 2007.
Post-Graduate Training
Medicine Internship, St. Luke’s Roosevelt Hospital, 2007-2008.
Radiology Residency, Columbia University Medical Center, 2008-2012.
Nuclear Radiology Fellowship, Columbia University Medical Center, 2012-2013.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Itmat Expertise

Molecular Imaging / Nuclear Medicine
CAR T cell Immunotherapy
Novel Radiotracer Development

Description of Research Expertise

My research focuses on oncologic applications of molecular imaging, with an emphasis on developing new imaging tools for the rapidly growing field of cancer immunotherapy. I am particularly interested in the development of novel radiotracers / reporter genes for CAR T cell tracking, as well as the development of radiolabeled antibodies for PET imaging of the immune system. To address these research areas, my laboratory utilizes an interdisciplinary team with expertise in a variety of scientific fields, including organic chemistry, radiochemistry, molecular biology, biochemistry, and bioengineering. Many of these translational research projects begin with in vitro studies and animal models, however the goal of every project is clinical application.

Selected Publications

Sellmyer MA, Richman SA, Lohith K, Hou C, Weng CC, Mach RH, O’Connor RS, Milone MC, Farwell MD: Imaging CAR T Cell Trafficking with eDFHR as a PET Reporter Gene. Mol Ther. 28(1): 42-51, January 2020 Notes: DOI: 10.1016/j.ymthe.2019.10.007

Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O'Donoghue JA, Ziolkowska M, Ruan S, Lyashchenko SK, Tsai F, Farwell M, Mitchell TC, Korn R, Le W, Lewis JS, Weber WA, Behera D, Wilson I, Gordon M, Wu AM, Wolchok JD: First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. J Nucl Med. 61(4): 512-519, April 2020 Notes: DOI: 10.2967/jnumed.119.229781

Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya A, Wubbenhorst B, Dorfman L, D’Andrea K, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier M, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao A, Mogg R, Xu W, Blumenschein W, Yearley JH, Linette G, Amaravadi RK, Schuchter LM, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC: A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma. Nat Med. 25(3): 454-461, Feb 2019.

Derakhshan JJ, Farwell MD: Prevalence and quantitative analysis of indium-111 pentetreotide (Octreoscan) uptake in the pancreatic head on SPECT/CT imaging: establishing a region of interest-based pathological uptake threshold. Nucl Med Commun. 40(7): 727-733, Jul 2019 Notes: doi: 10.1097/MNM.0000000000001022.

Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J: Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor–T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. 20(12): 1415-1418, December 2018 Notes: doi: 10.1016/j.jcyt.2018.10.003.

Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL: A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest. 128(5): 2116-2126, May 2018 Notes: doi: 10.1172/JCI97992.

Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH: A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer. 119(10): 1200-1207, November 2018.

Lohith K, Kwon S, Padakanti P, Thanna S, Hou C, Weng CC, Sellmyer M, Mach R, Farwell M: Radiosynthesis and in vitro evaluation of [11C]Shield-1, a PET probe for imaging CAR T cells that express the iCasp9 suicide gene. J Nucl Med. 59(Supplement 1): 61, May 2018 Notes: Oral Presentation.

Ahmed HS, Pantel AR, Metz JM, Plastaras JP, Farwell MD: FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma. Clin Nucl Med. 43(5): e139-e141, May 2018 Notes: doi: 10.1097/RLU.0000000000002035.

Chen X, Yang Y, Berger I, Khalid U, Patel A, Cai J, Farwell MD, Langer C, Aggarwal C, Albelda SM, Katz SI: Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. Oncotarget. 8(15): 24213-24223, April 2017 Notes: doi: 10.18632/oncotarget.12085.

Lohith K, Kwon S, Padakanti P, Lieberman B, Sandau U, Boison D, Mach R, Farwell M: Synthesis and initial characterization of [125I]-5-iodotubercidin, a radioligand for imaging adenosine kinase. J Nucl Med. 58(Supplement 1): 866, May 2017 Notes: Poster Presentation.

Mankoff DA, Farwell MD, Clark AS, Pryma DA: Making Molecular Imaging a Clinical Tool for Precision Oncology: A Review. JAMA Oncology. 3(5): 695-701, May 2017 Notes: doi: 10.1001/jamaoncol.2016.5084.

Farwell MD, Clark AS, Mankoff DA: How imaging biomarkers can inform clinical trials and clinical practice in the era of targeted cancer therapy. JAMA Oncology. 1(4): 421-422, Jul 2015 Notes: doi: 10.1001/jamaoncol.2015.0667.

Mankoff DA, Farwell MD, Clark AS, Pryma DA: How imaging can impact clinical trial design: molecular imaging as a biomarker for targeted cancer therapy. Cancer J. 21(3): 218-224, May-Jun 2015 Notes: doi: 10.1097/PPO.0000000000000116.

Farwell MD, Pryma DA, Mankoff DA: PET/CT imaging in cancer: Current applications and future directions. Cancer. 120(22): 3433-3445, November 2014 Notes: doi: 10.1002/cncr.28860.

Harris PE, Farwell MD, Ichise M: PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [18F]FP-DTBZ in baboons. Nucl Med Biol. 60(4): 60-64, January 2013 Notes: doi: 10.1016/j.nucmedbio.2012.09.003.

Farwell MD, Chong DJ, Iida Y, Bae SA, Easwaramoorthy B, Ichise M: Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide. Ann Nucl Med. 27(7): 618-624, Aug 2013 Notes: doi: 10.1007/s12149-013-0725-5.

back to top
Last updated: 08/30/2021
The Trustees of the University of Pennsylvania